{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-014619","form_type":"8-K","ticker":"ALBT","cik":"0001630212","company_name":"Avalon GloboCare Corp.","filed_at":"2025-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.241373+00:00","generated_at":"2026-05-26T16:35:05.879352+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"confidence":"high","headline":"Avalon GloboCare receives CNIPA patent allowance for CAR-T/NK cell therapy technology","bullets":["Notice of Allowance from China National Intellectual Property Administration for patent AVAR1901CN, co-developed with Arbele Limited.","Patent covers bispecific anti-CD19xCD22 CAR design and localized cytokine induction to enhance CAR cell cytotoxicity, survival, and proliferation.","Technology aims to improve expansion, manufacturing, and efficacy of CAR-T and CAR-NK cells for cancer treatment.","Extends Avalon's global IP footprint to China, supplementing existing U.S. and PCT protections.","CEO David Jin highlights potential for practical, cost-effective point-of-care cancer solutions."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-014619","json":"https://secwatch.observer/filing/0001213900-25-014619.json","markdown":"https://secwatch.observer/filing/0001213900-25-014619.md","text":"https://secwatch.observer/filing/0001213900-25-014619.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630212/000121390025014619/0001213900-25-014619-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630212/000121390025014619/ea0231383-8k_avalon.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T16:35:05.879352+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}